Gilead Sciences, Inc. Announces Phase 2 Results For Two Investigational All-Oral Sofosbuvir-Based Regimens For The Treatment Of Chronic Hepatitis C
Published: Apr 10, 2014
LONDON--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced data from two Phase 2 studies evaluating investigational all-oral regimens containing the nucleotide analog polymerase inhibitor sofosbuvir (SOF) for the treatment of chronic hepatitis C virus (HCV) infection. These data are being presented this week at the 49th Annual Meeting of the European Association for the Study of the Liver (The International Liver Congress 2014) in London.
Help employers find you! Check out all the jobs and post your resume.